Inactive Instrument

Flexion Therapeutics, Inc.

Equities

FLXN

US33938J1060

Biotechnology & Medical Research

Flexion Therapeutics : to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

December 07, 2020 at 04:30 pm EST

BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference. The virtual fireside chat is scheduled to begin at 2:15 p.m. ET on Friday, December 11, 2020.

To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.

Contact:

Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com

Source: Flexion Therapeutics, Inc.

2020 GlobeNewswire, Inc., source Press Releases

Latest news about Flexion Therapeutics, Inc.

Renovacor Names New CFO	22-03-28	MT
Pacira BioSciences Logs Higher Exparel, Iovera Sales in November	21-12-07	MT
North American Morning Briefing : Stock Futures -3-	21-11-22	DJ
Northland Securities Downgrades Flexion Therapeutics to Market Perform From Outperform, Price Target $10	21-11-19	MT
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Composite Index	21-11-19	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from S&P Global BMI Index	21-11-19	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from S&P TMI Index	21-11-19	CI
Pacira BioSciences, Inc. completed the acquisition of Flexion Therapeutics, Inc..	21-11-18	CI
Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Biotechnology Index	21-11-18	CI
Flexion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
North American Morning Briefing : Stock Futures -3-	21-10-20	DJ
FLEXION THERAPEUTICS : HC Wainwright Downgrades Flexion Therapeutics to Neutral From Buy, Price Target at $10	21-10-19	MT
North American Morning Briefing : Stock Futures -3-	21-10-13	DJ
FLEXION THERAPEUTICS : BMO Capital Downgrades Flexion Therapeutics to Market Perform Rating From Outperform, Adjusts Price Target to $12 From $20	21-10-12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral from Outperform Following News of Sale to Pacira BioSciences, Lowers PT to $10 from $14	21-10-12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral From Outperform, Cuts Price Target to $10 From $14	21-10-12	MT
FLEXION THERAPEUTICS : Raymond James Downgrades Flexion Therapeutics to Market Perform From Strong Buy	21-10-12	MT
Flexion Therapeutics : Health Care Stocks Sliding in Late Monday Trading	21-10-11	MT
Sector Update: Health Care	21-10-11	MT
NASDAQ 100 : Top Midday Gainers	21-10-11	MT
Protagonist Therapeutics : Health Care Stocks Trade Lower Premarket Monday	21-10-11	MT
DJ Industrial : Wall Street Declines on Soaring Energy Prices	21-10-11	MT
Flexion Therapeutics : Agrees to Be Acquired by Pacira BioSciences; Shares Soar Pre-Bell	21-10-11	MT
DJ Industrial : Top Premarket Gainers	21-10-11	MT
Pacira BioSciences : adds non-opioid pain drugs with $427.5 million Flexion buy	21-10-11	RE

Chart Flexion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Flexion Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. It is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. It markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The Company's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs